Company Profile: Lab21 Ltd

Pharmacogenetics is essential in the discovery of individual differences in metabolism and response to drugs, as well as in increasing the understanding of disease mechanisms. In addition, the use of biomarker assays is now critical in personalized medicine as specific variations in therapeutic targets can determine whether a drug is effective, particularly in oncology. Lab21 Ltd provides comprehensive and flexible biomarker assay development and commercialization services with an integrated structure that includes a full global development and commercialization capability together with accredited clinical service laboratories in both Europe and the USA. Lab21 adopts a platform and technology agnostic approach to molecular and immunodiagnostic development, and has an established and successful history of partnering with major pharmaceutical companies. Lab21 is becoming a significant global provider of diagnostic products and services, and is an ideal strategic partner for pharmaceutical and larger diagnostic companies to successfully deliver their biomarker assays to the patient.